#USA #Cambridge #Apnimed #Michael Kelly #Steven Spector

Apnimed Strengthens Leadership Team

In a strategic move to bolster its leadership and prepare for future growth, Apnimed, Inc., a clinical pharmaceutical company focused on novel oral therapies for sleep-related breathing disorders, has announced the appointments of Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs. This transition follows the recent appointment of Kevin Lind as Chief Executive Officer, signaling a carefully planned succession strategy amidst the company’s evolving landscape.

Key Appointments

Michael Kelly joins Apnimed with a rich background in healthcare finance, having over 25 years of experience that includes significant achievements in capital markets and mergers & acquisitions amounting to over $30 billion. Prior to his new role, he served as the Global Co-Head of Healthcare Investment Banking at Cantor Fitzgerald, where he played a pivotal role in leading a biopharmaceutical franchise on a global scale. As CFO, Kelly will oversee Apnimed’s capital strategies and its financial operations, with a focus on advancing the company’s flagship candidate, AD109, towards its potential commercialization.

Steven Spector also comes with a robust portfolio in the biotechnology sector. With more than 25 years of experience in legal, compliance, and business development roles, he was most recently the Executive Vice President and General Counsel at Longboard Pharmaceuticals. His experience is expected to enhance Apnimed’s legal framework and compliance capabilities as the company gears up for the anticipated commercial launch of AD109, a novel treatment for obstructive sleep apnea (OSA).

“Michael and Steven are joining Apnimed at a critical moment in our evolution,” stated Kevin Lind, CEO of Apnimed. Their extensive backgrounds in capital formation and business compliance are seen as essential for navigating the upcoming growth phase.

The Implications of AD109

AD109 is an investigational drug that aims to be the first of its kind pharmacological treatment for individuals suffering from OSA. Designed as a combination of aroxybutynin and atomoxetine, AD109 is intended to improve oxygenation during sleep while addressing the neuromuscular dysfunction that underlies airway collapse. This once-daily oral pill, taken at bedtime, is aimed at simplifying how OSA is treated compared to traditional methods that often include cumbersome devices or invasive surgeries.

Currently, OSA remains a significant health concern, impacting an estimated 80 million people in the United States alone, and over a billion individuals globally. The condition is characterized by the repeated collapse of the upper airway during sleep, leading to interruptions in breathing and subsequent oxygen deprivation. Without effective treatment, patients face grave long-term health risks including cardiovascular and neurological issues.

The introduction of a convenient oral option like AD109 could potentially expand the treatment landscape for OSA patients, allowing more people to gain access to effective therapies that enhance their overall well-being and sleep quality. Apnimed envisions a new paradigm in OSA treatment that focuses on less invasive, easily administered medications.

Conclusion

With the recruitment of Michael Kelly and Steven Spector, Apnimed is setting the stage for a new chapter in its growth trajectory. As they prepare for FDA approval processes for AD109, their leadership is expected to drive the company closer to redefining treatment methodologies for a condition that affects millions worldwide. Apnimed continues to innovate and develop solutions designed for improved patient outcomes in the realm of sleep health, with a commitment to expanding their therapeutic offerings and enhancing accessibility for those with OSA.